RCM - RCMテクノロジ―ズ （R1 RCM Inc.） RCMテクノロジ―ズRCMのチャート
RCMの企業情報
| symbol | RCM |
|---|---|
| 会社名 | RCM Technologies Inc. （RCMテクノロジ―ズ） |
| 分野（sector） | Consumer Services 消費者サービス |
| 産業（industry） | Other Consumer Services |
| 業種 | ヘルスケア施設_サ―ビス 工業（Industrials） |
| 概要 | 事業概要 アル1・アルシーエム（R1 RCM Inc.）は医療機関への収益サイクル管理（RCM）および医師諮問サービス（PAS）のプロバイダである。同社は、米国に拠点を置く病院およびその他の医療サービス提供者向けの収益サイクル・オペレーションの管理サービスの提供に従事している。主なサービスは、共同管理された関係または営業パートナー関係によって展開されるエンドツーエンドのRCMで構成される。同社のPASは、病院の訪問を、請求の目的で入院患者または外来患者の観察事例として分類するかどうかに関する支払人要件を満たすことを病院に支援する。同社はまた、政府および商業支払者に対して、上訴管理サービスのサポートを顧客に提供する。医師は医療記録の詳細な審査を行い、病院サービスのための医学的必要性と訴えを支持するための必要書類を特定する。 RCMテクノロジ―ズは米国の人材派遣会社。主に技術、医療、教育の分野の専門スタッフの紹介・派遣サ―ビスを展開。米国の企業、医療機関、教育機関へ技術専門家、エンジニア、医療従事者、看護師、介護師などの人材斡旋を行う。同社は1971年設立し、ニュ―ジャ―ジ―州に本社を置く。 R1 RCM Inc. is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1's proven and scalable operating models seamlessly complement a healthcare organization's infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. |
| 本社所在地 | 2500 McClellan Avenue Suite 350 Pennsauken NJ 08109-4613 USA |
| 代表者氏名 | Joseph Gerard Flanagan ジョセフ・ジェラード・フラナガン |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 312-324-7820 |
| 設立年月日 | 25934 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 3245人 |
| url | www.rcmt.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rcm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 5.50000 |
| 終値（lastsale） | 9.2 |
| 時価総額（marketcap） | 1011837868.4 |
| 時価総額 | 時価総額（百万ドル） 943.64880 |
| 売上高 | 売上高（百万ドル） 618.70000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1462.8488 |
| 当期純利益 | 当期純利益（百万ドル） -50.20000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 R1 RCM Inc revenues increased 91% to $355.2M. Net loss applicable to common stockholders increased 50% to $35.6M. Revenues reflect Net operating fees increase from $150.8M to $309.3M RCM services: other increase from $7.1M to $28M Incentive fees increase of 41% to $17.9M. Higher net loss reflects Selling general and administrative - B increase of 43% to $32M (expense). |
RCMのテクニカル分析
RCMのニュース
U.S. Revenue Cycle Management Market Analysis Report 2022-2030: Increase in Outsourcing of RCM / Growth of High-deductible Health Plans / Increasing Adoption of mHealth - ResearchAndMarkets.com 2022/05/25 15:20:00 Kwhen Finance
R1 RCM (RCM) Presents at 2022 RBC Capital Markets Healthcare Conference 2022/05/20 20:04:22 Seeking Alpha
The following slide deck was published by R1 RCM Inc.
R1 RCM Inc. – Consensus Indicates Potential 53.3% Upside 2022/05/15 19:32:29 DirectorsTalk
R1 RCM Inc. found using ticker (RCM) now have 8 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 35 and 28 with the average target price sitting at 32.25. With the stocks previous close at 21.04 this would imply there is a potential upside of 53.3%. The 50 day MA is 24.8 while the 200 day moving average is 23.42. The company has a market cap of $6,299m. Find out more information at: https://www.r1rcm.com [stock_market_widget type="chart" template="basic" color="green" assets="RCM" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $9,655m based on the market concensus. R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.
RCM Technologies: Impressive Growth Amid Tight Labor Market (NASDAQ:RCM) 2022/05/11 14:44:12 Seeking Alpha
RCM Technologies’ Q1 FY22 revenues soared by 84% year-on-year while EBITDA quintupled to $9.3 million. Click here to learn more about RCM stock.
R1 RCM Inc. (RCM) CEO Joe Flanagan on Q1 2022 Results - Earnings Call Transcript 2022/05/09 16:37:02 Seeking Alpha
R1 RCM Inc. (NASDAQ:NASDAQ:RCM) Q1 2022 Earnings Conference Call May 09, 2022 08:00 AM ET Company Participants Atif Rahim - Head, Investor Relations Joe Flanagan - President & Chief…
R1 RCM Inc. Consensus Indicates Potential 23.0% Upside 2022/02/20 11:30:35 DirectorsTalk
R1 RCM Inc. with ticker code (RCM) now have 9 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 35 and 27.5 calculating the average target price we see 31.72. With the stocks previous close at 25.79 this now indicates there is a potential upside of 23.0%. There is a 50 day moving average of 23.75 and the 200 day MA is 22.66. The company has a market capitalisation of $7,340m. Find out more information at: https://www.r1rcm.com [stock_market_widget type="chart" template="basic" color="green" assets=RCM" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $9,028m based on the market concensus. R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.
R1 RCM Reports Fourth Quarter and Full Year 2021 Results 2022/02/17 12:00:00 GlobeNewswire
MURRAY, Utah, Feb. 17, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months and year ended December 31, 2021.
Earnings Scheduled For February 17, 2022 2022/02/17 10:02:37 Benzinga
Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.
R1 RCM Q4 2021 Earnings Preview 2022/02/16 18:10:17 Seeking Alpha
R1 RCM (NASDAQ:RCM) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open.The consensus EPS Estimate is $0.14 (-44.0% Y/Y) and the consensus…
R1 RCM to Present at the SVB Leerink 11th Annual Global Healthcare Conference 2022/02/14 22:00:00 GlobeNewswire
MURRAY, Utah, Feb. 14, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 1:00 pm ET.
R1 RCM (RCM) Presents At 2021 Cantor Global Healthcare Conference - Slideshow 2021/10/01 17:09:39 Seeking Alpha
Robert W. Baird Stick to Their Buy Rating for R1 RCM By Investing.com 2021/09/24 09:13:35 Investing.com
Robert W. Baird Stick to Their Buy Rating for R1 RCM
R1 RCM to Present at Upcoming Investor Conferences 2021/08/31 21:00:00 Benzinga
MURRAY, Utah, Aug. 31, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM ), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at three upcoming investor conferences: The Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9 Full story available on Benzinga.com